AG-120, an oral agent targeting IDH1 mutations, is currently in a Phase I clinical trial sponsored by Servier, focusing on advanced hematologic malignancies. The trial's dual-phase design allows for both dose escalation and expansion, which could provide critical data on safety and efficacy. Given the increasing prevalence of IDH1 mutations in hematologic cancers, AG-120 has the potential to capture a significant share of the market for targeted therapies in this space. The competitive landscape includes other IDH inhibitors such as ivosidenib, necessitating a robust differentiation strategy based on clinical outcomes and safety profiles. Diligence should focus on the trial's progress, patient recruitment rates, and any emerging data that could influence market positioning.